Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
2 clinical trials · Condition
◉ Watch Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
| Record | Firm | Date |
|---|---|---|
| Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome (NCT04100434) | Tianjin Chest Hospital | 2021-01-01 |
Track Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor automatically
Every clearance here is in the API, with alerts when new ones post.